Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
3
ARCH Venture Partners, Hitachi Ventures
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners 
Hitachi Ventures 
Westlake BioPartners Similar startupsby what they do, their industry and backers
セレイドセラピューティクス - 細胞治療(造血幹細胞). Change the futurewith cell therapy.
About Us Cell Therapies for Life-Threatening Diseases LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient's…
We bring cell therapies to patients through innovative point-of-care manufacturing solutions.
Advance your cell therapy with Cellipont Bioservices, a leading cell therapy CDMO, offering tailored development, analytics, and cGMP…
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
Overview
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
News
ArsenalBio Announces New Focus on In Vivo CAR T Programs to Leverage Investment in T cell Engineering
Company to leverage its enabling technologies to expand into autoimmunity Strategic shift will align resources with the next phase of innovation in cell therapy Data from its clinical autologous cell therapy programs for solid tumors to be presented at a
Read more
Report
Report
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
Bristol Myers Squibb exercises an exclusive license option for ArsenalBio's AB-4000 series programs ArsenalBio is eligible for additional milestone payments and royalties as the programs advance South San Francisco, Calif. - January 13, 2025 - Arsenal Bio
Read more
Report
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., Arsena
Read more
Report
Arsenal Bio: Engineering Hope
Ken Drazan, Chairman, CEO and Co-Founder of Arsenal Bio, sits down with Nasdaq's Kristina Ayanian to celebrate their Series C and highlight the company's focus on treating cancer using engineered T cells.
Read more
Report
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer
South San Francisco, Calif. - September 16, 2024 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join
Read more
Report
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development
Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. - September 4, 2024 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for s
Read more
Report
ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers
Company to share research on new approaches to overcome the immunosuppressive tumor microenvironment and combat T cell exhaustion through integrated circuit T cell technology South San Francisco, Calif. - May 6, 2024 - Arsenal Biosciences, Inc. (ArsenalBi
Read more
Report
Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma
South San Francisco, Calif. - April 30, 2024 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that the first patient has bee
Read more
Report
Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research
Company to share preclinical data on the utility of engineered T cells intended for the treatment of ovarian, kidney, and other solid tumor cancers South San Francisco, Calif. - April 5, 2024 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage prog
Read more
Report
Show more news